L’hôpital Femme Mère Enfant est un des pôles du centre hospitalier universitaire de Lyon. Rattaché au groupement Est des HCL ou GHE, il est situé à Bron.

During the past decade, Hôpital Femme-Mère-Enfant conducted 127 clinical trials. In the 10-year time frame, 127 clinical trials started and 17 clinical trials were completed, i.e. on average, 13.4% percent of trials that started reached the finish line to date. In the past 5 years, 68 clinical trials started and 11 clinical trials were completed. i.e. 16.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Femme-Mère-Enfant" #1 sponsor was "Hospices Civils de Lyon" with 84 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "Vertex Pharmaceuticals Incorporated" with 5 trials sponsored, "Mirum Pharmaceuticals, Inc." with 4 trials sponsored and "Amgen" with 4 trials sponsored. Other sponsors include 58 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Femme-Mère-Enfant" #1 collaborator was "Ministry of Health, France" with 2 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 1 trials as a collaborator, "Association Clinique Thérapeutique Infantile du val de Marne" with 1 trials as a collaborator, "Association Française contre les Myopathies (AFM), Paris" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Femme-Mère-Enfant" are "Cystic Fibrosis" (8 trials), "Achondroplasia" (3 trials), "Juvenile Idiopathic Arthritis" (3 trials), "Progressive Familial Intrahepatic Cholestasis (PFIC)" (3 trials) and "Alagille Syndrome" (2 trials). Many other conditions were trialed in "Hôpital Femme-Mère-Enfant" in a lesser frequency.

Most popular intervention types in "Hôpital Femme-Mère-Enfant" are "Drug" (61 trials), "Other" (59 trials), "Biological" (14 trials), "Device" (12 trials) and "Behavioral" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Baricitinib" (5 trials), "ELX/TEZ/IVA" (5 trials), "IVA" (5 trials) and "Blood sampling" (4 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Femme-Mère-Enfant" are 132 trials for "All" genders, 28 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are 59 active trials in "Hôpital Femme-Mère-Enfant". 6 are not yet recruiting, 36 are recruiting, 13 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 80 completed trials in Hôpital Femme-Mère-Enfant, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Femme-Mère-Enfant, 2 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 44 trials that are defined as “Not Applicable".